Bactiguard strengthens its sales organization by appointing Erik Düring head of European sales

Bactiguard is expanding its business, with focus on Europe, the Middle East,
Asia, South America and Southern Africa. The recruitment of Erik Düring as
Regional Sales Director Europe is an important step in strengthening the sales
and marketing organization, which supports the company’s distributors and
develops the markets where Bactiguard has direct sales.
“Bactiguard is in a rapid expansion phase. We have developed our own product
portfolio, which prevents hospital acquired infections, and successfully
established distributors in Asia, the Middle East, South America and Southern
Africa. We will now shift focus to strengthening our sales and marketing
function to expand sales.

Erik Düring has solid international experience from the medtech industry. With
Erik as the regional sales director for Europe, we strengthen our competence and
can really start focusing on developing the Swedish and other European markets,”
says Johan Rugfelt CEO.

Erik Düring has a broad background in the medtech industry, including both
product development and sales. He has been employed by Radi Medical Systems and
St Jude Medical and, most recently, was the CEO of CMA Microdialysis AB.

Erik Düring has a Master of Science in Mechanical Engineering and will take up
his new position on August 1.
For further information, please contact:

Johan Rugfelt, CEO

johan.rugfelt@bactiguard.se

Switchboard: +46 8 440 58 80

Cecilia Edström, Director of Communications

cecilia.edstrom@bactiguard.se

Mobile: +46 722 262 328
Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare
associated infections, reducing the use of antibiotics and saving lives by
developing and supplying infection prevention solutions to the healthcare
industry. The company’s patented coating prevents healthcare associated
infections by reducing bacterial adhesion and growth on medical devices.
Bactiguard®-coated urinary catheters are market leading in the US and Japan, and
in recent years the company has developed its own product portfolio of coated
catheters for the urinary and respiratory tract and the blood stream. Bactiguard
is currently in a strong expansion phase, focused on new markets in the EU,
Middle East, Asia and South America. The company reported  sales of
approximately SEK 130 million in 2013, has 60 employees, headquarters in
Stockholm and production facilities in Markaryd and Malaysia. More information
is available at www.bactiguard.se